Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Total Non-Current Liabilities (2018 - 2025)

Nanobiotix has reported Total Non-Current Liabilities over the past 8 years, most recently at $110.3 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 39.1% year-over-year to $110.3 million; the TTM value through Dec 2025 reached $110.3 million, up 39.1%, while the annual FY2025 figure was $110.3 million, 39.1% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $110.3 million at Nanobiotix, up from $57.8 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $110.3 million in Q4 2025 and troughed at $38.7 million in Q2 2022.
  • A 5-year average of $58.7 million and a median of $51.7 million in 2021 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: fell 27.73% in 2022 and later surged 60.64% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $43.6 million in 2021, then rose by 14.31% to $49.9 million in 2022, then fell by 1.04% to $49.3 million in 2023, then surged by 60.64% to $79.3 million in 2024, then soared by 39.1% to $110.3 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for NBTX at $110.3 million in Q4 2025, $57.8 million in Q2 2025, and $79.3 million in Q4 2024.